Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04810910
Other study ID # INEO-P-005
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 30, 2021
Est. completion date March 30, 2025

Study information

Verified date November 2021
Source Zhejiang Provincial People's Hospital
Contact Yang Liu, M.D.
Phone 13666601475
Email yangliuqq2003@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This research study is evaluating a new type of pancreatic cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for pancreatic cancer patients following surgical resection and adjuvant chemotherapy. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable pancreatic cancer, so as to provide a new personalized therapeutic strategy. It is known that cancer patients have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the cancer to come back in the future. The study will examine the safety of the vaccine when given at several different time points and will examine the participant's blood cells for signs that the vaccine induced an immune response.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 30, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Must freely sign informed consent; 2. Aged 18 to 70 years old; 3. Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma; 4. Must provide all exons of tumor tissue sequencing data, transcriptome sequencing data and the peripheral blood of all exons sequencing data; 5. ECOG score is 0 or 1; 6. Completed an R0 or R1 surgical resection as determined by pathology; 7. Completion of at least 4 months of adjuvant chemotherapy with ticgio monotherapy or mFOLFIRINOX; 8. Completion of imaging records 1 week before personalized immunotherapy, including but not limited to full-body PET-CT and brain MRI, 9. The end of chemotherapy is followed by a one-week natural washout period; 10. Haematological index: - White blood cells = 3500 / MCL - Lymphocytes > 800/ MCL - neutrophils > 1500/ MCL - Platelets > 100000 / MCL - Hemoglobin >10.0g/dL - Total serum bilirubin <1.5× upper limit of normal value (ULN) - AST/ALT<2.0 times the upper limit of normal - Serum creatinine <1.5 times the upper limit of normal; 11. Pregnant, lactating women and women of child-bearing age must have a negative pregnancy test within 7 days before entering the group, and short-term have no fertility plan, and are willing to take protective measures (contraception or other birth control methods) before and during the clinical trial; 12. Good compliance, able to follow research protocols and follow-up procedures. Exclusion Criteria: 1. Evidence of disease recurrence or metastasis following surgical resection at any time prior to the first vaccination administration. 2. Diagnosed as other malignant tumor; 3. No neoantigen was found in the sequencing data; 4. There have been bone marrow or stem cell transplants; 5. Received systemic glucocorticoids with immunosuppressants; 6. Received other polypeptide inoculation 4 weeks before treatment; Patients may not be vaccinated with other polypeptides 8 weeks after the last individualized tumor targeted polypeptides trentment; 7. With HIV, HCV, HBV infection, severe asthma, autoimmune disease, immunodeficiency or treated with immunosuppressive drugs; 8. Uncontrolled complications include, but are not limited to, active infection, symptomatic congestive heart failure, unstable angina pectoris, and arrhythmias; 9. Infected with herpes virus (except those with scabs of more than 4 weeks); 10. Infected with respiratory virus (except those who have recovered for more than 4 weeks); 11. Have severe coronary or cerebrovascular disease, or other conditions considered ineligible by the investigator; 12. Drug abuse. Clinical, psychological or social factor result in affecting informed consent or research implementation; 13. Have a history of drug or polypeptide allergies, or people who are allergic to other potential immunotherapies.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
iNeo-Vac-P01
iNeo-Vac-P01 (peptides): 300 mcg per peptide
Other:
GM-CSF
GM-CSF: 40 mcg

Locations

Country Name City State
China Zhejiang Provincial People's Hospital Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Zhejiang Provincial People's Hospital Hangzhou Neoantigen Therapeutics Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Measurement of CD4/CD8 T lymphocyte subsets 2 years
Other The polypeptide antigen - induced IFN-? T cells responses 2 years
Other Peripheral blood T cell receptor sequencing analysis 2 years
Primary Number of participants experiencing clinical and laboratory adverse events (AEs) Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 1 years
Primary Relapse Free Survival(RFS) Time from surgery to any recurrence 4 years
Secondary Overall Survival(OS) Time from surgery to death or last follow-up 4 years
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Not yet recruiting NCT05529940 - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) Phase 3
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Recruiting NCT02243007 - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT05679050 - Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Withdrawn NCT01694589 - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer Phase 0
Active, not recruiting NCT03138720 - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer Phase 2
Completed NCT01298011 - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer Phase 2
Completed NCT06363084 - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Completed NCT01992705 - Borderline Pancreas Study: FOLFIRINOX +SBRT Early Phase 1
Recruiting NCT05624918 - A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma Phase 2
Completed NCT02047513 - Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Phase 2
Completed NCT02115022 - EUS vs. MDCT in Pancreatic Malignancy
Recruiting NCT03492671 - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer Phase 2
Terminated NCT05546411 - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer Phase 2
Not yet recruiting NCT06172036 - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab Phase 2
Recruiting NCT05788744 - Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer N/A
Recruiting NCT04737551 - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting NCT03822936 - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma Phase 2
Completed NCT03435536 - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer N/A